



**INTERNATIONAL JOURNAL OF
PHARMACEUTICAL SCIENCES**
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: <https://www.ijpsjournal.com>



Review Article

Advancements in Radiopharmaceutical Sciences for Oncology: Current Innovations and Future Challenges

Dr. Rahul Kumar Soni*, Debendra Suman, Saurabh Maurya, Madhulika Tiwari, Shilpi Biswas

Department of Pharmacology & Therapeutics, King George's Medical University, UP, Lucknow-226003, India.

ARTICLE INFO

Published: 15 Aug. 2025

Keywords:

Radiopharmaceuticals,
Oncology, Theranostics,
Targeted therapy

DOI:

10.5281/zenodo.16885394

ABSTRACT

Radiopharmaceutical science has now become a pivotal way of advancing research and therapies within oncology and expanding the future of oncology itself, largely due to dramatic strides in radionuclide development, targeted therapies and theranostics. Much of this scientific progress is now catalyzed by modern developments in radiochemistry, delivery systems based on nanotechnology, and diagnosis via artificial intelligence, which allows for greater precision and efficacy with therapeutic response. From a clinical perspective, some of these recent developments have been very successful in treating neuroendocrine tumours and treatment-resistant cancers like BRAF mutant tumours. As we look into the future, intelligent imaging devices, and interdisciplinary technology implementation has the potential to revolutionize personalized patient care in oncology. The extent to which we can realize these benefits will depend on how fast we can create the necessary infrastructure to support it, as well as to unite organization in academia, vendors and regulatory bodies. The trajectory of radiopharmaceutical sciences is dependent on establishing collaboration, increasing clinical standards to maintain protocols and enhancing the applied efficacy of preclinical technologies to provide safe and successful clinical care. We will achieve transformational outcomes for cancer patients all over the globe, elevating the standard of precision oncology.

INTRODUCTION

Cancer remains one of the most common causes of morbidity and mortality all over the globe, leading to the deaths of millions each year(1); (2); (3); (4). Unfortunately, while many advances have been

made with regards to different treatment modalities in surgery, chemotherapy, and immunotherapy, numerous types of cancers still manifest resistance to conventional therapies. It is this complex, heterogeneous nature of tumors that necessitates the formulation of very much targeted

***Corresponding Author:** Dr. Rahul Kumar Soni

Address: Department of Pharmacology & Therapeutics, King George's Medical University, UP, Lucknow-226003, India.

Email ✉: dr.rahulsonipharmakgmu@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



and effective therapeutic approaches for the betterment of patient outcomes and quality of life in general (5); (6); (5). Within treatment of oncology, the emerging field of radiopharmaceutical sciences represents the application of the principles of nuclear medicine combined with molecular imaging to better diagnosis, staging, and treatment of cancers. Using radio labeled compounds; clinicians may visualize and quantify biological processes down at the molecular level, thus offering the prospect of earlier detection of malignancies and better insights into treatment responses (7); (8);(9);(10). Moreover, targeted radiopharmaceutical therapies are characterized by the delivery of cytotoxic radiation specifically to tumor cells, sparing damage to adjacent healthy tissues, rendering them a potentially highly promising strategy in personalized cancer treatment (11). This review aims to provide an overview of the advancements in radiopharmaceutical sciences for oncology, new innovations, and the new challenges ahead. This will encompass novel radiotracers, improved radiochemistry techniques, and upcoming theranostics approaches that combine diagnostic imaging with targeted therapy. From a critical appraisal of the clinic applications and technological developments, this review will elucidate the transformative vision radiopharmaceuticals hold for precision oncology and outline prospects for future research warranted to enhance their clinical utility even further (12).

2. Historical Perspective and Evolution of Radiopharmaceuticals

2.1 Early Milestones in Radiopharmaceutical Development

The origins of radiopharmaceutical sciences trace back to the groundbreaking discoveries of radioactivity by Henri Becquerel and Marie Curie in the late 19th and early 20th centuries (13); (14); (15);(16); (17). These early experiments laid the scientific foundation for harnessing radioactive isotopes in medicine. A seminal milestone was the clinical application of radioactive iodine in the treatment of thyroid disorders during the 1940s, which demonstrated that targeted radioactivity

could selectively affect diseased tissues (18); (19);(20);(21). Early research also explored the use of radium and other isotopes in both diagnostic imaging and therapeutic contexts, albeit with limited specificity. These pioneering efforts catalyzed the formal establishment of nuclear medicine, setting the stage for subsequent innovations in radiopharmaceutical synthesis, quality control, and clinical applications.

2.2 Transition from Diagnostic to Therapeutic Applications

Initially, the primary role of radiopharmaceuticals was diagnostic. Radiotracers such as technetium-99m became central to nuclear medicine, providing non-invasive methods to image organ function and detect pathological changes, including bone metastases and cardiac abnormalities (22). As the field matured, advancements in radiochemistry and imaging modalities enabled a transition toward therapeutic uses. Clinicians began to recognize that the targeted delivery of radioisotopes could administer cytotoxic radiation directly to tumor cells while limiting exposure to surrounding healthy tissues. This realization led to the development of radionuclide therapies, wherein agents were designed not only to visualize tumors but also to treat them by emitting therapeutic doses of radiation. The integration of improved dosimetry and imaging feedback further refined these approaches, supporting a shift from a purely diagnostic role to a dual function in personalized treatment regimens (22);(23);(24);(25).

2.3 Emergence of Theranostics in Oncology

By combining diagnostic imaging with targeted therapy, theranostics truly signify a revolution in the ever-growing and ever-changing field of radiopharmaceuticals. This approach is indeed innovative in allowing the assessment of tumor biology at the same time as sited therapy, enabling personalized cancer care. One of the more impactful examples of this paradigm has been the use of lutetium-177 labeled compounds in neuroendocrine tumors, exploiting the same molecular target both for imaging and therapy



(26);(27). Beyond neuroendocrine applications, theranostic strategies have also branched out into prostate cancer with the advent of PSMA-targeted agents, all of which are significantly more capable of allowing patient stratification and therapeutic outcomes. The dual function of theranostic agents increases their treatment efficacy through precise targeting, streamlining pre- and post-treatment dosimetry, and fostering a reasonable balance between tumor control and normal tissue sparing (28); (29); (30); (31). Such integrated approaches currently lie at the heart of precision oncology, driving ongoing research and clinical trials to refine radiopharmaceutical design and expand their therapeutic potential.

3. Current Innovations in Radiopharmaceutical Sciences

3.1 Advances in Radiochemistry and Radio labeling Techniques

3.1.1 Novel Synthetic Approaches

The latest technological progress has established new synthetic techniques to effectively produce radio-labeled compounds. The methods optimize radionuclide attachment to targeting molecules and aim for simple chemical conditions to protect biomolecules' bioactivity (32);(33).

3.1.2 Improved Specific Activity and Stability

Effective imaging and therapy require radiopharmaceuticals to possess enhanced specific activity and elevated stability. The field of radiotracer development has targeted two main areas that aim to decrease background impurities alongside refining labeling techniques for maintaining storage quality and performance in living systems (33);(34). Research improvements delivered better radio agents through improved visual forecastable therapeutic results(35).

3.2 Development of Novel Radionuclides

3.2.1 Alpha Emitters, Beta Emitters, and Auger Electron Emitters

Targeted radiotherapy received significant enhancement through the creation of multiple new radionuclides. The treatment requirements for precise localized damage rely on beta emitters and Auger electron emitters together with alpha emitters(36);(37);(38);(39);(40);(41);(42).

3.2.2 Emerging Isotopes for Targeted Applications

Two newly discovered radioactive elements, terbium-161 and copper-64, produce special forms of decay behavior, which help them, serve as effective tools for medical imaging and therapy. These radionuclides demonstrate promising capabilities for improved dosimetry, more precise targeting and lower side effects than traditional therapeutic agents (43);(44);(45).

3.3 Targeted Radiopharmaceuticals

3.3.1 Radio immunotherapy

Radioimmunotherapy exploits the specificity of monoclonal antibodies to deliver targeted radiation to cancer cells. Recent clinical trials have demonstrated significant therapeutic efficacy, especially in hematological tumors, through the high specificity of antibodies chemoconjugated with potent radio therapeutics(46);(47);(48).

3.3.2 Peptide Receptor Radionuclide Therapy (PRRT)

PRRT uses peptides as therapeutic agents that target specific receptors overexpressed on certain tumors such as neuroendocrine tumors. Advances in peptide engineering and radiolabeling have improved this targeting while reducing toxicity, making PRRT an established treatment option in oncology (49);(50);(51);(52).

3.3.3 Small Molecule-Based Agents

Small molecule radiopharmaceuticals may have rapid tissue penetration resulting in fast clearance of non-target tissues(53);(54). There have been numerous innovations over the years aiming to improve the pharmacokinetics and biodistribution



of these small molecule agents. This is especially true for their use in imaging and therapeutic procedures in the short term(55);(55);(56);(57).

3.4 Theranostic Approaches

3.4.1 Dual Diagnostic and Therapeutic Agents

Theranostic approaches, dual diagnostic and therapeutic agents theranostics. The theranostic agents represent a combination of diagnostic imaging and therapy in one compound that allows clinic to simultaneously assess tumor characteristics and biodistributions while delivering a targeted treatment(58); (59);(60). This involves the real-time monitoring of therapeutic efficiency and personalization of the dose (61);(62).

3.4.2 Personalized Medicine and Treatment Optimization

The integration of theranostics into clinical practice has paved the way for personalized medicine in oncology. By tailoring treatment plans based on individual patient imaging and dosimetric data, clinicians can achieve better outcomes while minimizing adverse effects(63);(64). Current research is focused on further improving these strategies transitioning

from the relatively simple amalgamation into patient-specific therapeutic approaches (65);(66);(35);(67);(68).

3.5 Advances in Imaging Modalities

3.5.1 PET, SPECT, and Hybrid Imaging Techniques

At the very leading edge of nuclear imaging, PET and SPECT are currently employed(69);(70). The contemporary technology of the past few years, associated with the development of the new hybrid imaging such as PET/CT and PET/MRI, equipped with higher resolution detectors, has enormously enhanced the spatial resolution and sensitivity of the tumor imaging (71);(72);(73).

3.5.2 Quantitative Imaging and Biomarker Assessment

This quantitative imaging technique aims to render accurate assessment of uptake of the radiotracer within the tumors to analyze tumor metabolism and receptor expression (74);(75). In this quantitative approach, it is through the identification of imaging biomarkers that a therapeutic response target could be recognized, allowing real-time treatment decisions to be altered (76);(77).

Table 1: Summary of Key Innovations in Radiopharmaceutical Sciences

Innovation	Description	Representative Agents/Isotopes
Novel Synthetic Approaches	Efficient, mild reaction conditions using click chemistry and innovative catalytic methods.	Various biomolecules labeled under optimized conditions.
Improved Specific Activity & Stability	Enhanced purity and labeling conditions to maintain radiotracer integrity and optimize dosimetry.	Technetium-99m based agents and similar compounds.
Alpha, Beta, & Auger Electron Emitters	Utilization of diverse emission types for tailored therapeutic effects.	Actinium-225, Lutetium-177, Indium-111, etc.
Emerging Isotopes	Investigation of novel radionuclides with unique decay properties for enhanced targeting.	Terbium-161, Copper-64
Radioimmunotherapy	Use of monoclonal antibodies to deliver radionuclides specifically to tumor cells.	Ibritumomab tiuxetan, Zevalin
Peptide Receptor Radionuclide Therapy (PRRT)	Targeting of overexpressed peptide receptors in tumors to deliver therapeutic radiation.	Lutetium-177 DOTATATE



Small Molecule-Based Agents	Low molecular weight compounds that achieve rapid tissue penetration and fast clearance from non-target tissues.	PSMA-targeted agents, others
Dual Diagnostic and Therapeutic Agents	Single agents used for both imaging and treatment, enabling real-time therapy monitoring.	Lutetium-177, Copper-64 labeled compounds
Personalized Medicine & Treatment Optimization	Integration of imaging and dosimetry data to tailor and optimize individual treatment strategies.	Various theranostic protocols
PET, SPECT, and Hybrid Imaging Techniques	Advanced imaging modalities that combine structural and functional imaging for improved diagnostic accuracy.	PET/CT, SPECT/CT, PET/MRI systems
Quantitative Imaging and Biomarker Assessment	Precise quantification of radiotracer uptake to guide treatment decisions and monitor response.	Standardized Uptake Value (SUV) measurements

Table 1 above summarizes all innovations in the advancement of radiochemistry, the furthering of radionuclides, the emergence of targeted therapies, the development of theranostics, and their subsequent imaging modalities.

4. Clinical Translation and Applications in Oncology

4.1 Success Stories and Case Studies

Radiopharmaceuticals have moved into clinical applications from preclinical studies and have proved to be effective in a variety of tumors where they are applied with the great fidelity required for therapeutic gain.

4.1.1 Clinical Impact of BRAF-Targeted Radiopharmaceuticals

Preclinical research on radiopharmaceuticals currently exists in clinical applications as these drugs demonstrate exact targeting capabilities that yield better cancer treatment results in multiple types of cancer. Here are some notable examples:

4.1.1 Clinical Impact of BRAF-Targeted Radiopharmaceuticals

Molecular imaging combined with targeted radiotherapy paves the way for personalized cancer treatment to enable mutation-targeted

treatment options. These pairing lets health care practitioners (HCPs) see and target tumors using their molecular data. As a result, HCPs can boost the effectiveness and accuracy in targeting with minimal side effects allowing for more precise treatments (78); (79). Another key approach is to turn some small-molecule inhibitors into radiolabeled therapy. Vemurafenib is one such selective BRAF inhibitor designed to target the BRAF V600E mutation often found in melanoma and other cancers. Scientists have modified the chemistry of vemurafenib and tagged it with iodine-131 (¹³¹I), which results in ¹³¹I-labeled vemurafenib, to deliver toxic radiation to cancer cells with the BRAF V600E mutation. This method combines targeted therapy and radiotherapy in one agent (80); (81). This delivery also shows a radiotheranostic strategy that helps with advanced tumor imaging and offers a powerful way to remove mutant tumor cells, while sparing normal tissues.

4.1.2 Applications in Neuroendocrine Tumors (NETs)

Patients with neuroendocrine tumors (NETs) that have excessive somatostatin receptors (SSTRs) subtype 2 (SSTR2) are optimal candidates for Peptide Receptor Radionuclide Therapy (PRRT). PRRT is a targeted therapy that couples somatostatin analogs with therapeutic radioisotopes. The treatment allows the physician to deliver radiation to the tumor cells while sparing



the neighboring healthy tissue. PRRT is very effective in treating NETs that have metastasized or cannot be surgically removed (82); (83). An example of PRRT is ^{177}Lu -DOTATATE. ^{177}Lu -DOTATATE is composed of DOTATATE (a somatostatin analog) and lutetium-177 (^{177}Lu) (a radioisotope that emits beta particles). Once administered to the patient, ^{177}Lu -DOTATATE binds to somatostatin receptors on the tumor cells. The tumor cells take in the tracer ^{177}Lu -DOTATATE, directly delivering radiation to the cancer (84); (85). The ^{177}Lu -DOTATATE not only kills cancer cells but also helps many patients stabilize their disease and relieve symptoms. The results of studies including NETTER-1 show that ^{177}Lu -DOTATATE helps patients live longer without worsening disease and improves other quality-of-life metrics compared to standard of care treatments (86); (87); (88).

4.1.3 Prostate-Specific Membrane Antigen (PSMA)-Targeted Therapy

The expression of Prostate-Specific Membrane Antigen (PSMA) at high levels becomes frequent in prostate cancer cells that have developed castration-resistant prostate cancer (CRPC). The bean-like compound ^{177}Lu -PSMA-617 demonstrates effective results in both metastatic prostate cancer diagnosis and treatment applications. The administration of radiopharmaceuticals to patients with advanced disease results in substantial PSA-level decreases and improved imaging detection combined with extended survival outcomes according to research findings (89); (90). The dual diagnostic and therapeutic properties of the same molecule drive a major development of personalized cancer treatment for prostate cancer.

4.1.4 HER2-Targeted Radiotherapy

Radioactive and specific HER2 receptor-targeted breast cancer treatment can provide therapeutic benefits to patients whose tumors express high levels of HER2 receptors through the use of ^{111}In -trastuzumab antibody administration.

Clinical research findings indicate that patients achieve better metastatic lesion detection and better response rates to therapeutic treatments when standard therapies combine with those preparations (91).

4.1.5 Radiolabeled Antibodies for Lymphoma

Radiolabeled monoclonal antibody administration has led to a major improvement in Non-Hodgkin's Lymphoma (NHL) treatment. ^{90}Y -ibritumomab tiuxetan consists of monoclonal antibody components that target CD20 antigens found on B-cell lymphomas. The clinical trial results achieved outstanding patient responses from patients whose disease relapsed or did not respond to initial therapy, after which medical professionals gained a valuable therapeutic alternative for chemotherapy-recalcitrant patients (92).

4.2 Challenges in Clinical Trial Design and Implementation

While radiopharmaceuticals have been associated with favorable clinical results in the management of many cancers, there are many major barriers that inhibit the regular use of radiopharmaceuticals in real-world clinical care. The most prominent limitation is the selectivity of the radiopharmaceutical clinical trials, all of which seek specific molecular- or receptor-targeted signatures. Although this helps to direct therapies to specific groups of patients whom will benefit most, it also limits who can participate in these trials and subsequently excludes large members of the general oncology population, with recruitment partly challenging in the case of rare or heterogeneous tumors; for example, ^{177}Lu -DOTATATE and similarly, ^{225}Ac -PSMA-617 clinical trials have strict eligibility criteria for subjecting inclusivity based on receptor expression or mutation status, which further complicates patient recruitment into these trials (93);(94); (95). Further complicating the pursuit of radiopharmaceutical research is the operational and structural aspects of the radiopharmaceutical process and program. In addition to the added complexity of using advanced imaging modalities (for example, PET/CT or SPECT), and on-site



radiopharmacy, investigating (and treatment) with radiopharmaceuticals requires the involvement and assistance of regional trained radiological staff, and ongoing support from radiation safety and waste disposal units. All participating institutions must have aligned data collection and communication processes to assure regulatory compliance and assure all parties of data security. This is especially true for Good Manufacturing Practices (GMP) or Good Clinical Practices (GCP) (96); (97). A further limitation is radiation toxicity. Because radiation safety is a primary concern for radiopharmaceuticals, patients will undoubtedly incur radiation exposure from our agents delivering beta or alpha particles to tumors. This unintended exposure affects surrounding healthy tissues, most concerningly bone marrow, kidneys and liver, all of which can be affected by ionizing radiation, including hematologic or renal toxicity (98);(99); (100). These factors are particularly pertinent in at-risk patients with comorbidities, by way of organ dysfunction or impaired clearance mechanisms, thus warrant a more individualised approach, including personalized dosimetry and toxicity monitoring measures (101). There are also limits to clinical application because of access and complexity of commercial regulatory restrictions. For inclusion as a study and ultimately, a commercially available product, there many radiopharmaceuticals will be produced at a specialized facility, have short half-life and thus can be constrained by geography. In addition to radioactive materials and all regulatory guidelines

regarding safety accordingly, these limits can lead to excessive costs and delays in translation to clinics.

4.3 Regulatory Considerations and Quality Control

The strict regulatory criteria exist for radiopharmaceuticals since they pose risks from radiation-related exposure hazards. The production of radiopharmaceuticals requires manufacturers to establish and follow approved procedures that serve to meet regulatory needs. Medical facilities obeying Good Manufacturing Practice (GMP) standards depend on these guidelines to run their entire radiopharmaceutical manufacturing and quality assessment processes. The production of radiopharmaceuticals adheres to guidelines developed by the International Atomic Energy Agency (IAEA) and the Food and Drug Administration (FDA) as well as the European Medicines Agency (EMA). The clinical applications of several radiopharmaceuticals in oncology, targeted molecules or pathways, specific cancer types, clinical outcomes, and references are summarized in the table 2 below. The included radiopharmaceuticals encompass targeted agents for mutation-specific therapy, peptide receptor radionuclide therapy (PRRT), PSMA-based treatments, HER2-targeted radiotherapy, and radio labeled antibodies for lymphoma.

Application	Radiopharmaceutical	Targeted Molecule/Pathway	Cancer Type	Clinical Outcome
BRAF-Targeted Therapy	¹³¹ I-labeled Vemurafenib	BRAF V600E Mutation	Melanoma, Colorectal Cancer	Enhanced tumor control and improved survival.
PRRT for Neuroendocrine Tumors	¹⁷⁷ Lu-DOTATATE	Somatostatin Receptor	Neuroendocrine Tumors	Prolonged progression-free survival and overall survival.

PSMA-Targeted Radiotherapy	^{177}Lu -PSMA-617	Prostate-Specific Membrane Antigen (PSMA)	Prostate Cancer	Significant reduction in PSA levels and improved imaging sensitivity.
HER2-Targeted Radiotherapy	^{111}In -trastuzumab	HER2 Receptor	Breast Cancer	Effective detection and treatment of HER2-positive tumors.
Radio labeled Antibodies for Lymphoma	^{90}Y -ibritumomab tiuxetan	CD20 Antigen	Non-Hodgkin's Lymphoma	Improved response rates in relapsed or refractory patients.

5. Future Challenges and Opportunities

5.1 Technological Barriers

5.1.1 Production and Distribution of Radionuclides

The industrial production of short-lived medical radionuclides currently poses a substantial technical difficulty. The production of efficient radionuclides depends heavily on special reactor systems combined with cyclotron devices and complex chemical processing capabilities. Establishing and supporting these facilities requires significant expenses which creates additional difficulties in production operations. Systematic delivery of radionuclides faces substantial hurdles because of scarce infrastructure together with logistical difficulties. The success of radiopharmaceutical development demands international partnerships and infrastructure investments to eliminate these barriers. Radiochemical automation brings several benefits to the field through its ability to increase precision alongside safety measures and production speed and reduce human handling requirements. The development of durable automated production systems that remain cost efficient proves difficult to achieve. Academic institutions alongside industrial companies together with regulatory organizations need to work jointly to resolve these challenges and establish wider clinical access for radiopharmaceuticals.

5.2. Regulatory and Safety Challenges

Radiopharmaceuticals are under complex and arduous regulatory challenges elicited by their radioactive nature and dual diagnostic-therapeutic applications. To obtain regulatory approval, radiopharmaceuticals must meet radiation safety compliance requirements along with those for quality assurance and standard clinical protocols. The global use of radiopharmaceuticals becomes further complicated by inconsistent regulatory standards between countries. Approved procedures resulting from international cooperative efforts may also provide scientists means to accelerate clinical approval processes (102). Radionuclide use faces economic challenges including high manufacturing costs and limited access to lab facilities, with complex supply delivery systems hampering the general adoption of radiopharmaceutical technologies. Along such lines, the economics of the pharmaceutical industry would suffer due to such high research and development costs. These advanced radiopharmaceutical therapies also require the professional implementation of automated systems in moving from research and development to commercial production.

5.3 Emerging Trends and Research Directions

5.3.1 Integration with Artificial Intelligence and Machine Learning

The combination of Artificial Intelligence (AI) with Machine Learning (ML) presents promising prospects for the radiopharmaceutical sciences which includes advanced radiological engineering



alongside improved diagnostic features with predicted therapeutic outcomes. The operation of AI algorithms relies upon their capability to handle large data sets efficiently while they identify new targets before designing special treatment plans per person. The development of automated radiopharmaceutical production becomes possible through artificial intelligence models resulting in better scalability and higher efficiency (103).

5.3.2 Nanotechnology and Novel Delivery Systems

The combination of liposomes alongside dendrimers and nanoparticles forms nanotechnology-based delivery systems which result in enhanced targeted delivery and reduce side effects. Engineering processes for these systems work to boost the therapeutic ratio of radiopharmaceutical drugs to enhance their clinical usefulness. Scientists produce single-functioning theranostic delivery platforms through nanotechnology which integrates both therapy and imaging traits (104).

5.3.3 Biomarker-Driven Approaches for Patient Stratification

Successful patient profiling through biomarkers becomes essential because scientists try to establish unique biomarkers as guides for directed radiopharmaceutical treatment solutions. Biomarkers enable healthcare approaches to develop personalized medicine tactics that yield low adverse effects which results in superior treatment results. Biomarker-based patient stratification helps medical research identify suitable patient populations to expedite clinical trial authorizations resulting in accelerated access for new treatments (105); (106).

6. CONCLUSION

6.1 Summary of Key Innovations and Clinical Impacts

Scientific research in radiopharmaceutical sciences has experienced meaningful progress through the development of new radionuclides and targeted therapeutic methods and theranostic methodologies. Modern advancements in radiochemistry methods and artificial intelligence diagnostic equipment accompanying nanotechnology delivery vehicles have led to increased precision while improving treatment effects for cancer patients. The successful clinical application of research has generated favorable results when targeting neuroendocrine cancers together with BRAF-mutated treatment-resistant diseases.

6.2 Future Outlook and the Potential for Transforming Oncology

The field of radiopharmaceutical sciences shows great potential for progress through the integration of new technology together with interdisciplinarity to create better personalized cancer treatment methods. The ongoing developments in infrastructure together with automation systems and AI-based methods will be fundamental for removing current obstacles while enhancing therapeutic processes. Academic institutions must join forces with industrial companies together with regulatory bodies to create new pharmaceutical agents while ensuring proper implementation and safety.

6.3 Call for Collaborative Efforts in Research and Clinical Translation

The complete realization of radiopharmaceutical sciences requires better working relationships between researchers and clinicians with industry stakeholders and government bodies. Standardized protocols together with upgraded regulatory frameworks and knowledge-sharing platforms are fundamental elements to convert preclinical research into clinical success. Global patient outcomes will receive exponential improvement because collaborative initiatives speed up the rate of innovation.



REFERENCES

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*. 2018;68(6):394-424.
2. Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. *The Lancet Global Health*. 2020;8(2):e191-e203.
3. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. *European journal of cancer*. 2018;103:356-87.
4. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. *CA: a cancer journal for clinicians*. 2023;73(1):17-48.
5. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *cell*. 2011;144(5):646-74.
6. Hanahan D. Hallmarks of cancer: new dimensions. *Cancer discovery*. 2022;12(1):31-46.
7. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. *Journal of Nuclear Medicine*. 2002;43(5):693-713.
8. Goldenberg DM. Cancer therapy with radiolabeled antibodies: CRC Press Boca Raton, FL; 1995.
9. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. *Journal of Nuclear Medicine*. 2005;46(1 suppl):115S-27S.
10. Fritzberg AR, Berninger RW, Hadley SW, Wester DW. Approaches to radiolabeling of antibodies for diagnosis and therapy of cancer. *Pharmaceutical research*. 1988;5:325-34.
11. Ailawadhi S, Pafundi D, Peterson J. Advances and future directions in radiopharmaceutical delivery for cancer treatment. *Expert Review of Anticancer Therapy*. 2025(just-accepted).
12. Dhoundiyal S, Srivastava S, Kumar S, Singh G, Ashique S, Pal R, et al. Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation. 2024;29(1):26.
13. Radvanyi P, Villain J. The discovery of radioactivity. *Comptes Rendus Physique*. 2017;18(9):544-50.
14. Becquerel H. Sur les radiations émises par phosphorescence. *Comptes rendus de l'Academie des Sciences, Paris*. 1896;122:420-1.
15. Becquerel H. Sur les radiations invisible emises par les corps phosphorescents. *Comptes rendus*. 1896;122:501-3.
16. Becquerel H. Sur les radiations invisibles emises parles corps phosphorescents. *Compt rend*. 1896;122:689-94.
17. Mould RF. The discovery of radium in 1898 by Maria Sklodowska-Curie (1867-1934) and Pierre Curie (1859-1906) with commentary on their life and times. *The British Journal of Radiology*. 1998;71(852):1229-54.
18. Becker DV, Sawin CT, editors. Radioiodine and thyroid disease: the beginning. *Seminars in nuclear medicine*; 1996: Elsevier.
19. Daniels GH, Ross DS. Radioactive iodine: a living history. *Thyroid*. 2023;33(6):666-73.
20. Sheremeta MS, Korchagina MO, Pesheva ED, Fadeev VV. Radioactive iodine in the treatment of Graves' disease: history and modern concept of radionuclide therapy. *Terapevticheskii arkhiv*. 2022;94(10):1211-5.
21. Sgouros G, Roeske JC, McDevitt MR, Palm S, Allen BJ, Fisher DR, et al. MIRD Pamphlet No. 22-Radiobiology and Dosimetry of Alpha-Particle Emitters for Targeted Radionuclide



- Therapy. Alpha-Particle Emitter Dosimetry. 2009;1-105.
22. Smith JT, Bowes M, Denison F. Modelling the dispersion of radionuclides following short duration releases to rivers: Part 1. Water and sediment. *Science of the Total Environment*. 2006;368(2-3):485-501.
 23. Sgouros G, Hobbs RF, editors. *Dosimetry for radiopharmaceutical therapy*. Seminars in nuclear medicine; 2014: Elsevier.
 24. Capala J, Graves SA, Scott A, Sgouros G, James SS, Zanzonico P, et al. Dosimetry for radiopharmaceutical therapy: current practices and commercial resources. *Journal of Nuclear Medicine*. 2021;62(Supplement 3):3S-11S.
 25. O'Donoghue J, Zanzonico P, Humm J, Kesner A. Dosimetry in radiopharmaceutical therapy. *Journal of Nuclear Medicine*. 2022;63(10):1467-74.
 26. Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. *Bioconjugate chemistry*. 2011;22(10):1879-903.
 27. Pandit-Taskar N, O'Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, et al. First-in-Human Imaging with ⁸⁹Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. *Journal of Nuclear Medicine*. 2016;57(12):1858-64.
 28. Hofman M, Violet J, Sandhu S, Ferdinandus J, Thang SP, Irvani A, et al. High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial. *Society of Nuclear Medicine*; 2018.
 29. Rizzo LY, Theek B, Storm G, Kiessling F, Lammers T. Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. *Current opinion in biotechnology*. 2013;24(6):1159-66.
 30. Ryu JH, Lee S, Son S, Kim SH, Leary JF, Choi K, et al. Theranostic nanoparticles for future personalized medicine. *Journal of controlled release*. 2014;190:477-84.
 31. Xu Y, Dang D, Zhu H, Jing X, Zhu X, Zhang N, et al. Boosting the AIEgen-based phototheranostic platform by balancing radiative decay and non-radiative decay. *Materials Chemistry Frontiers*. 2021;5(11):4182-92.
 32. Shahzad K, Majid ASA, Khan M, Iqbal MA, Ali A. Recent advances in the synthesis of (99mTechnetium) based radiopharmaceuticals. *Reviews in Inorganic Chemistry*. 2021;41(3):151-98.
 33. Derdau V, Elmore CS, Hartung T, McKillican B, Mejuch T, Rosenbaum C, et al. The future of (radio) - labeled compounds in research and development within the life science industry. *Angewandte Chemie International Edition*. 2023;62(52):e202306019.
 34. de Roode KE, Joosten L, Behe M. Towards the magic radioactive bullet: improving targeted radionuclide therapy by reducing the renal retention of radioligands. *Pharmaceuticals*. 2024;17(2):256.
 35. Dhoundiyal S, Srivastava S, Kumar S, Singh G, Ashique S, Pal R, et al. Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation. *European Journal of Medical Research*. 2024;29(1):26.
 36. Pirovano G, Wilson TC, Reiner T. Auger: The future of precision medicine. *Nuclear medicine and biology*. 2021;96:50-3.
 37. Idrissou MB, Pichard A, Tee B, Kibedi T, Poty S, Pouget J-P. Targeted radionuclide therapy using auger electron emitters: the quest for the right vector and the right radionuclide. *Pharmaceutics*. 2021;13(7):980.
 38. Randhawa P, Olson AP, Chen S, Gower-Fry KL, Hoehr C, Engle JW, et al. Meitner-Auger Electron Emitters for Targeted Radionuclide



- Therapy: Mercury-197m/g and Antimony-119. *Current radiopharmaceuticals*. 2021;14(4):394-419.
39. Tranel J, Feng FY, St James S, Hope TA. Effect of microdistribution of alpha and beta-emitters in targeted radionuclide therapies on delivered absorbed dose in a GATE model of bone marrow. *Physics in Medicine & Biology*. 2021;66(3):035016.
40. Zhang J, Qin S, Yang M, Zhang X, Zhang S, Yu F. Alpha - emitters and targeted alpha therapy in cancer treatment. *iRADIOLOGY*. 2023;1(3):245-61.
41. Stokke C, Kvasheim M, Blakkisrud J. Radionuclides for targeted therapy: physical properties. *Molecules*. 2022;27(17):5429.
42. Frago Costa P, Shi K, Holm S, Vidal-Sicart S, Kracmerova T, Tosi G, et al. Surgical radioguidance with beta-emitting radionuclides; challenges and possibilities: a position paper by the EANM. *European journal of nuclear medicine and molecular imaging*. 2024;51(10):2903-21.
43. Van Laere C, Koole M, Deroose CM, Van de Voorde M, Baete K, Cocolios TE, et al. Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside. *Theranostics*. 2024;14(4):1720.
44. Müller C, van der Meulen NP, Schibli R. Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics. *European Journal of Nuclear Medicine and Molecular Imaging*. 2023;50(11):3181-4.
45. Favaretto C, Grundler PV, Talip Z, Köster U, Johnston K, Busslinger SD, et al. Terbium-149 production: a focus on yield and quality improvement towards preclinical application. *Scientific Reports*. 2024;14(1):3284.
46. Cheal SM, Chung SK, Vaughn BA, Cheung N-KV, Larson SM. Pretargeting: a path forward for radioimmunotherapy. *Journal of Nuclear Medicine*. 2022;63(9):1302-15.
47. Zhou Z, Guan B, Xia H, Zheng R, Xu B. Particle radiotherapy in the era of radioimmunotherapy. *Cancer letters*. 2023;567:216268.
48. Rondon A, Rouanet J, Degoul F. Radioimmunotherapy in oncology: overview of the last decade clinical trials. *Cancers*. 2021;13(21):5570.
49. Hofland J, Brabander T, Verburg FA, Feelders RA, de Herder WW. Peptide receptor radionuclide therapy. *The Journal of Clinical Endocrinology & Metabolism*. 2022;107(12):3199-208.
50. Merola E, Grana CM. Peptide receptor radionuclide therapy (PRRT): innovations and improvements. *Cancers*. 2023;15(11):2975.
51. Gubbi S, Koch CA, Klubo-Gwiedzinska J. Peptide receptor radionuclide therapy in thyroid cancer. *Frontiers in endocrinology*. 2022;13:896287.
52. Lu X, Lu C, Yang Y, Shi X, Wang H, Yang N, et al. Current Status and Trends in Peptide Receptor Radionuclide Therapy in the Past 20 Years (2000–2019): A Bibliometric Study. *Frontiers in Pharmacology*. 2021;12.
53. Chaturvedi S, Mishra AK. Small molecule radiopharmaceuticals—a review of current approaches. *Frontiers in Medicine*. 2016;3:5.
54. Gee AD, Bongarzone S, Wilson AA. Small molecules as radiopharmaceutical vectors. *Radiopharmaceutical Chemistry*. 2019:119-36.
55. Jeong JM. Application of a small molecule radiopharmaceutical concept to improve kinetics. Springer; 2016. p. 99-101.
56. H. Elsinga P, AJO Dierckx R. Small molecule PET-radiopharmaceuticals. *Current pharmaceutical design*. 2014;20(14):2268-74.
57. Sgouros G. Radiopharmaceutical therapy. *Health physics*. 2019;116(2):175-8.

58. Ballinger JR. Theranostic radiopharmaceuticals: established agents in current use. *The British journal of radiology*. 2018;91(1091):20170969.
59. Sarkar P, Khatana S, Mukherjee B, Shukla J, Das B, Dutta G. Application of Radiopharmaceuticals in Diagnostics and Therapy. *Next-Generation Nanobiosensor Devices for Point-Of-Care Diagnostics*: Springer; 2022. p. 227-49.
60. Lindsley CW, Müller CE, Bongarzone S. Diagnostic and therapeutic radiopharmaceuticals. ACS Publications; 2022. p. 835-7.
61. Ballinger JR. Radiopharmaceuticals in clinical diagnosis and therapy. *Basic Sciences of Nuclear Medicine*: Springer; 2021. p. 103-18.
62. Knapp F, Dash A, Knapp F, Dash A. Introduction: Radiopharmaceuticals play an important role in both diagnostic and therapeutic nuclear medicine. *Radiopharmaceuticals for therapy*. 2016:3-23.
63. Graves SA, Hobbs RF, editors. Dosimetry for optimized, personalized radiopharmaceutical therapy. *Seminars in radiation oncology*; 2021: Elsevier.
64. Pandit-Taskar N, Iravani A, Lee D, Jacene H, Pryma D, Hope T, et al. Dosimetry in clinical radiopharmaceutical therapy of cancer: practicality versus perfection in current practice. *Journal of Nuclear Medicine*. 2021;62(Supplement 3):60S-72S.
65. Sgouros G, Bodei L, McDevitt MR, Nedrow JR. Radiopharmaceutical therapy in cancer: clinical advances and challenges. *Nature reviews Drug discovery*. 2020;19(9):589-608.
66. Srivastava SC. A Bridge not too Far: Personalized Medicine with the use of Theragnostic Radiopharmaceuticals. *J Postgrad Med Educ Res*. 2013;47:31-46.
67. Srivastava SC, editor Paving the way to personalized medicine: production of some promising theragnostic radionuclides at Brookhaven National Laboratory. *Seminars in nuclear medicine*; 2012: Elsevier.
68. Kraeber-Bodéré F, Barbet J. Challenges in nuclear medicine: innovative theranostic tools for personalized medicine. *Frontiers Media SA*; 2014. p. 16.
69. Crişan G, Moldovean-Cioroianu NS, Timaru D-G, Andrieş G, Căinap C, Chiş V. Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade. *International journal of molecular sciences*. 2022;23(9):5023.
70. Delbeke D, Schöder H, Martin WH, Wahl RL, editors. Hybrid imaging (SPECT/CT and PET/CT): improving therapeutic decisions. *Seminars in nuclear medicine*; 2009: Elsevier.
71. Schillaci O. Hybrid SPECT/CT: a new era for SPECT imaging? *European journal of nuclear medicine and molecular imaging*. 2005;32:521-4.
72. Bockisch A, Freudenberg LS, Schmidt D, Kuwert T, editors. Hybrid imaging by SPECT/CT and PET/CT: proven outcomes in cancer imaging. *Seminars in nuclear medicine*; 2009: Elsevier.
73. Alqahtani FF. SPECT/CT and PET/CT, related radiopharmaceuticals, and areas of application and comparison. *Saudi Pharmaceutical Journal*. 2023;31(2):312-28.
74. Weber WA, Schwaiger M, Avril N. Quantitative assessment of tumor metabolism using FDG-PET imaging. *Nuclear medicine and biology*. 2000;27(7):683-7.
75. Zimmer L, Luxen A. PET radiotracers for molecular imaging in the brain: past, present and future. *Neuroimage*. 2012;61(2):363-70.
76. Paulmurugan R, Oronsky B, Brouse CF, Reid T, Knox S, Scicinski J. Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm. *Theranostics*. 2013;3(6):437.



77. Bai J-W, Qiu S-Q, Zhang G-J. Molecular and functional imaging in cancer-targeted therapy: current applications and future directions. *Signal Transduction and Targeted Therapy*. 2023;8(1):89.
78. Yordanova A, Biersack HJ, Ahmadzadehfar H. Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors. *Journal of clinical medicine*. 2020;9(11).
79. Kendi AT, Moncayo VM, Nye JA, Galt JR, Halkar R, Schuster DM. Radionuclide therapies in molecular imaging and precision medicine. *PET clinics*. 2017;12(1):93-103.
80. Rbah-Vidal L, Vidal A, Billaud EM, Besse S, Ranchon-Cole I, Mishellany F, et al. Theranostic approach for metastatic pigmented melanoma using ICF15002, a multimodal radiotracer for both PET imaging and targeted radionuclide therapy. *Neoplasia*. 2017;19(1):17-27.
81. Zou Z, Zhong L. Anaplastic thyroid cancer: Genetic roles, targeted therapy, and immunotherapy. *Genes & Diseases*. 2024:101403.
82. Kwekkeboom DJ, Kam BL, Van Essen M, Teunissen JJ, van Eijck CH, Valkema R, et al. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. *Endocrine-related cancer*. 2010;17(1):R53.
83. Wang L, Tang K, Zhang Q, Li H, Wen Z, Zhang H, et al. Somatostatin Receptor - Based Molecular Imaging and Therapy for Neuroendocrine Tumors. *BioMed research international*. 2013;2013(1):102819.
84. Chakravarty R, Chakraborty S. A review of advances in the last decade on targeted cancer therapy using ¹⁷⁷Lu: Focusing on ¹⁷⁷Lu produced by the direct neutron activation route. *American Journal of Nuclear Medicine and Molecular Imaging*. 2021;11(6):443.
85. Kamaldeep, Wanage G, Loharkar S, Das T, Basu S, Banerjee S. Estimation of absorbed doses of indigenously produced “direct-route” lutetium-177-[¹⁷⁷Lu] Lu-DOTA-TATE PRRT in normal organs and tumor lesions in patients of metastatic neuroendocrine tumors: comparison with no-carrier-added [¹⁷⁷Lu] Lu-DOTA-TATE and the trend with multiple cycles. *Cancer Biotherapy & Radiopharmaceuticals*. 2022;37(3):214-25.
86. Strosberg JR, Caplin ME, Kunz PL, Ruzniewski PB, Bodei L, Hendifar A, et al. ¹⁷⁷Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. *The Lancet Oncology*. 2021;22(12):1752-63.
87. Strosberg JR, Srirajaskanthan R, El-Haddad G, Wolin EM, Chasen BA, Kulke MH, et al. Symptom diaries of patients with midgut neuroendocrine tumors treated with ¹⁷⁷Lu-DOTATATE. *Journal of nuclear medicine*. 2021;62(12):1712-8.
88. Becx MN, Minczeles NS, Brabander T, de Herder WW, Nonnekens J, Hofland J. A clinical guide to peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE in neuroendocrine tumor patients. *Cancers*. 2022;14(23):5792.
89. Hoffmann MA, Buchholz H-G, Wieler HJ, Miederer M, Rosar F, Fischer N, et al. PSA and PSA kinetics thresholds for the presence of ⁶⁸Ga-PSMA-11 PET/CT-detectable lesions in patients with biochemical recurrent prostate cancer. *Cancers*. 2020;12(2):398.
90. de Vos II, Luiting HB, Roobol MJ. Active surveillance for prostate cancer: past, current, and future trends. *Journal of Personalized Medicine*. 2023;13(4):629.



91. Müller V, Banys-Paluchowski M, Friedl TW, Fasching PA, Schneeweiss A, Hartkopf A, et al. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. *ESMO open*. 2021;6(6):100299.
92. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90–labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. *Journal of clinical oncology*. 2002;20(10):2453-63.
93. NM S. VISIT SNMMI’S.
94. Yadav MP, Ballal S, Sahoo RK, Bal C. Efficacy and safety of 225 Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study. *European journal of nuclear medicine and molecular imaging*. 2022;1-12.
95. Demirci E, Selçuk NA, Beydağı G, Ocak M, Toklu T, Akçay K, et al. Initial findings on the use of [225Ac] Ac-DOTATATE therapy as a theranostic application in patients with neuroendocrine tumors. *Molecular Imaging and Radionuclide Therapy*. 2023;32(3):226.
96. Rana B, Yadav D, Yadav S. Strategic Association for Quality Excellence: Coordination Between GMP, GLP, GCP, Metrology, QC, and QA. *Handbook of Quality System, Accreditation and Conformity Assessment*: Springer; 2024. p. 1-21.
97. van Huizen LS, Ahaus C. The Road to Excellence: A Case Study of the Application of GMP, ISO 9001 and the EFQM Excellence Model in a Nuclear Medicine Department. *Quality in Nuclear Medicine*: Springer; 2016. p. 3-21.
98. Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. *European journal of nuclear medicine and molecular imaging*. 2015;42:5-19.
99. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. *New England Journal of Medicine*. 2017;376(2):125-35.
100. Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, et al. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. *Pancreas*. 2017;46(6):707-14.
101. Hicks R, Czernin J, Herrmann K. Advancing Nuclear Medicine in Australia over 3 Decades: A Conversation Between Rodney Hicks, Johannes Czernin, and Ken Herrmann. *Journal of Nuclear Medicine*. 2022;63(1):1-4.
102. Kim KH, Kim JS, Jang WI, Yoon S. Efficacy Evaluation of Alpha/Beta Radioactivity Screening in Urine Samples using Liquid Scintillation Counting. *Journal of Radiation Industry*. 2024;18(2):101-7.
103. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. *Nature medicine*. 2019;25(1):44-56.
104. Obimba DC, Esteva C, Nzouatcham Tsicheu EN, Wong R. Effectiveness of Artificial Intelligence Technologies in Cancer Treatment for Older Adults: A Systematic Review. *Journal of clinical medicine*. 2024;13(17):4979.
105. Devarakonda S, Govindan R. Biomarker-Driven Staging—Are We There Yet? *JAMA Network Open*. 2019;2(12):e1917052-e.

106. Simon R. Stratification and partial ascertainment of biomarker value in biomarker-driven clinical trials. *Journal of biopharmaceutical statistics*. 2014;24(5):1011-21.

HOW TO CITE: Dr. Rahul Kumar Soni*, Debendra Suman, Saurabh Maurya, Madhulika Tiwari, Shilpi Biswas, *Advancements in Radiopharmaceutical Sciences for Oncology: Current Innovations and Future Challenges*, *Int. J. of Pharm. Sci.*, 2025, Vol 3, Issue 8, 1781-1796. <https://doi.org/10.5281/zenodo.16885394>

